The Acute Management of Newly Diagnosed Atrial Fibrillation in Critically Ill Patients. The Role of Landiolol in Clinical Practice.

Published: 22 November 2021
Likes: 14
Average (rating)
No ratings
Your rating

Overview

Physicians to manage an arrhythmia in critically ill patients should take into consideration many parameters.  The choice of a suitable medicinal agent is a very challenging decision-making process. Critically ill patients frequently present with comorbidities as heart failure.  In challenging cases, the assistance of cardiologists is often requested.

Rapibloc is a medicinal agent for life-critical conditions, where it is desirable to safely and rapidly reduce heart rate with limited effect in blood pressure and inotropy (e.g. pts in sepsis, pts with heart failure).

After this webinar has finished, we would love to hear your thoughts. Please click the link here: https://forms.office.com/r/aAK8DhK8pJ

Learning Objectives

  • ICU patient profile
  • Limitations of current therapeutic options for the management of AF in ICU patients
  • Landiolol properties (Pharmacokinetic – Pharmacodynamic profile)
  • AF Triggers During Critical Illness
  • Rate vs Rhythm control
  • Landiolol is sepsis pts
  • Safe co-administration of landiolol in patients on catecholamine support

Target Audience

  • Cardiologists who advice Intensivists for the management of arrhythmias in ICU
  • Cardiologists who work in ICUs
  • Cardiologists who work in Coronary Care Units

Agenda

Session 1

Welcome and Introduction

Presentation 1

A novel super-selective intravenous beta-blocker in management Atrial Fibrillation (AF) during ICU stay

Presentation 2

Rate vs Rhythm control for management POAF in critical ill patients. Examples from life experience

Session 2

Q&A

This broadcast is supported by
logo